Edwards Lifesciences Corporation revised earnings guidance for the full year of 2022. For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86.72 USD | -0.80% | +1.72% | +13.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.73% | 52.26B | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B | |
+24.30% | 31.41B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022